PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 21, 2019New England Journal of Medicine2,910 citationsOpen Access

Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

View Full Paper
SRSuresh S. RamalingamJVJohan VansteenkisteDPDavid Planchard

Key Points

  • To evaluate the overall survival of osimertinib compared to comparator EGFR-TKIs in untreated advanced NSCLC with an EGFR mutation.
  • Randomized trial (NCT02296125) comparing osimertinib with comparator EGFR-TKIs.
  • Participants had untreated advanced non-small cell lung cancer (NSCLC) with an EGFR mutation.
  • Assessment of safety profiles and overall survival outcomes.
  • Patients receiving osimertinib had longer overall survival compared to the comparator EGFR-TKI group.
  • Safety profile of osimertinib was similar to comparator EGFR-TKIs despite longer exposure.

Abstract

Among patients with previously untreated advanced NSCLC with an EGFR mutation, those who received osimertinib had longer overall survival than those who received a comparator EGFR-TKI. The safety profile for osimertinib was similar to that of the comparator EGFR-TKIs, despite a longer duration of exposure in the osimertinib group. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ramalingam et al. (2019) studied this question.

synapsesocial.com/papers/69d73939c74376700bf30cc5https://doi.org/10.1056/nejmoa1913662
Ask AI
Helpful
Bookmark
Share
View Full Paper